Loading...

Cytori Therapeutics

DB:XMPN
Snowflake Description

High growth potential with imperfect balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
XMPN
DB
$7M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Cytori Therapeutics, Inc., a therapeutics company, together with its subsidiaries, develops regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for various medical conditions. The last earnings update was 26 days ago. More info.


Add to Portfolio Compare Print
  • Cytori Therapeutics has significant price volatility in the past 3 months.
XMPN Share Price and Events
7 Day Returns
-6.6%
DB:XMPN
-0.1%
DE Biotechs
1%
DE Market
1 Year Returns
-89.1%
DB:XMPN
-7.4%
DE Biotechs
-5.6%
DE Market
XMPN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Cytori Therapeutics (XMPN) -6.6% 44.2% -5.9% -89.1% -99.5% -99.9%
DE Biotechs -0.1% 6% -6.7% -7.4% 53.2% 11.6%
DE Market 1% 6.1% 8.4% -5.6% 10.9% 13.8%
1 Year Return vs Industry and Market
  • XMPN underperformed the Biotechs industry which returned -7.4% over the past year.
  • XMPN underperformed the Market in Germany which returned -5.6% over the past year.
Price Volatility
XMPN
Industry
5yr Volatility vs Market

XMPN Value

 Is Cytori Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Cytori Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is €0.225.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Cytori Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Cytori Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:XMPN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-1.74
NasdaqCM:CYTX Share Price ** NasdaqCM (2019-04-24) in USD $0.31
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.73x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.72x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Cytori Therapeutics.

DB:XMPN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:CYTX Share Price ÷ EPS (both in USD)

= 0.31 ÷ -1.74

-0.18x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cytori Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Cytori Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Cytori Therapeutics's expected growth come at a high price?
Raw Data
DB:XMPN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.18x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
54.3%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Cytori Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Cytori Therapeutics's assets?
Raw Data
DB:XMPN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.35
NasdaqCM:CYTX Share Price * NasdaqCM (2019-04-24) in USD $0.31
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.72x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:XMPN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:CYTX Share Price ÷ Book Value per Share (both in USD)

= 0.31 ÷ 0.35

0.88x

* Primary Listing of Cytori Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cytori Therapeutics is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Cytori Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Cytori Therapeutics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

XMPN Future Performance

 How is Cytori Therapeutics expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
54.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Cytori Therapeutics expected to grow at an attractive rate?
  • Cytori Therapeutics's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Cytori Therapeutics's earnings growth is expected to exceed the Germany market average.
  • Cytori Therapeutics's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:XMPN Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:XMPN Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 54.3%
DB:XMPN Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 32.3%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.6%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:XMPN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:XMPN Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 37 9 1
2022-12-31 33 7 1
2021-12-31 28 4 1
2020-12-31 17 -12 -11 2
2019-12-31 7 -6 -13 3
DB:XMPN Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 7 -12 -15
2018-09-30 6 -14 -21
2018-06-30 7 -15 -21
2018-03-31 6 -17 -24
2017-12-31 6 -18 -27
2017-09-30 8 -18 -23
2017-06-30 9 -19 -24
2017-03-31 10 -19 -24
2016-12-31 11 -20 -22
2016-09-30 12 -20 -20
2016-06-30 12 -21 -13
2016-03-31 12 -20 -2

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Cytori Therapeutics's earnings are expected to grow significantly at over 20% yearly.
  • Cytori Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:XMPN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Cytori Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:XMPN Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.21 0.21 0.21 1.00
2022-12-31 0.17 0.17 0.17 1.00
2021-12-31 0.11 0.11 0.11 1.00
2020-12-31 -0.59 -0.45 -0.72 2.00
2019-12-31 -0.72 -0.62 -0.80 3.00
DB:XMPN Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -1.74
2018-09-30 -3.38
2018-06-30 -4.28
2018-03-31 -5.64
2017-12-31 -8.23
2017-09-30 -8.52
2017-06-30 -10.03
2017-03-31 -12.31
2016-12-31 -12.75
2016-09-30 -13.40
2016-06-30 -10.58
2016-03-31 -1.95

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Cytori Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Cytori Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Cytori Therapeutics has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

XMPN Past Performance

  How has Cytori Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Cytori Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Cytori Therapeutics does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Cytori Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Cytori Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Cytori Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Cytori Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:XMPN Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 6.65 -15.12 8.36
2018-09-30 6.05 -21.15 9.59
2018-06-30 6.51 -21.14 9.67
2018-03-31 6.45 -23.53 11.06
2017-12-31 6.41 -26.66 11.19
2017-09-30 7.91 -23.32 11.26
2017-06-30 8.75 -23.90 12.07
2017-03-31 10.07 -24.25 11.90
2016-12-31 11.38 -22.05 12.17
2016-09-30 11.73 -19.89 12.07
2016-06-30 11.60 -12.98 12.18
2016-03-31 12.23 -2.13 12.41
2015-12-31 11.66 -19.41 12.43
2015-09-30 12.05 -23.57 13.63
2015-06-30 10.68 -34.48 16.34
2015-03-31 8.51 -50.76 19.43
2014-12-31 7.60 -38.54 22.36
2014-09-30 7.29 -41.65 24.83
2014-06-30 8.90 -37.53 25.30
2014-03-31 9.87 -28.91 25.22
2013-12-31 12.20 -26.18 25.06
2013-09-30 16.06 -19.96 24.94
2013-06-30 14.67 -25.95 25.05
2013-03-31 16.78 -30.62 24.96
2012-12-31 14.50 -32.28 25.16
2012-09-30 10.01 -35.36 25.39
2012-06-30 10.84 -32.45 26.32 -6.12

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Cytori Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Cytori Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Cytori Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Cytori Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Cytori Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

XMPN Health

 How is Cytori Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Cytori Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Cytori Therapeutics's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Cytori Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Cytori Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is not covered by short term assets, assets are 0.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Cytori Therapeutics Company Filings, last reported 3 months ago.

DB:XMPN Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 5.23 14.20 5.26
2018-09-30 6.14 14.01 6.81
2018-06-30 4.75 13.84 3.08
2018-03-31 8.48 13.73 5.90
2017-12-31 13.00 13.62 9.55
2017-09-30 7.82 13.50 4.78
2017-06-30 11.23 14.52 9.03
2017-03-31 7.36 16.09 6.26
2016-12-31 10.99 17.64 12.56
2016-09-30 13.67 17.40 14.92
2016-06-30 18.72 17.16 20.04
2016-03-31 7.74 16.92 9.36
2015-12-31 12.21 16.68 14.34
2015-09-30 5.00 16.42 18.97
2015-06-30 2.26 16.21 23.84
2015-03-31 -23.20 25.68 13.20
2014-12-31 -5.70 25.40 14.62
2014-09-30 -3.29 25.81 7.85
2014-06-30 1.19 26.84 12.76
2014-03-31 2.40 26.57 12.80
2013-12-31 3.13 26.29 15.51
2013-09-30 -3.19 26.02 10.21
2013-06-30 1.26 25.74 13.62
2013-03-31 2.37 20.39 16.40
2012-12-31 6.46 22.69 25.72
2012-09-30 -9.73 24.95 17.63
2012-06-30 0.55 24.78 25.77
  • Cytori Therapeutics's level of debt (271.8%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (841.7% vs 271.8% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Cytori Therapeutics has less than a year of cash runway based on current free cash flow.
  • Cytori Therapeutics has less than a year of cash runway if free cash flow continues to reduce at historical rates of -14.4% each year.
X
Financial health checks
We assess Cytori Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Cytori Therapeutics has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

XMPN Dividends

 What is Cytori Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Cytori Therapeutics dividends.
If you bought €2,000 of Cytori Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Cytori Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Cytori Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:XMPN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:XMPN Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Cytori Therapeutics has not reported any payouts.
  • Unable to verify if Cytori Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Cytori Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Cytori Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Cytori Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Cytori Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Cytori Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

XMPN Management

 What is the CEO of Cytori Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Marc Hedrick
COMPENSATION $846,039
AGE 55
TENURE AS CEO 5 years
CEO Bio

Dr. Marc H. Hedrick, M.D., has been the President of Cytori Therapeutics, Inc. (also known as Macropore Biosurgery Inc.) since May, 2004 and has been its Chief Executive Officer since April 2, 2014. Dr. Hedrick served as the Principal Financial Officer of Cytori Therapeutics, Inc. from August 2014 to September 2, 2014. Dr. Hedrick joined Cytori Therapeutics, Inc. as the Chief Scientific Officer and Medical Director in October 2002. He co-founded StemSource Inc. and served as the President and Chief Executive Officer and Director. He is a Plastic Surgeon and was an Associate Professor of Surgery and Pediatrics at the University of California, Los Angeles (UCLA) and From 1998 to 2005, has directed the Laboratory of Regenerative Bioengineering and Repair for the Department of Surgery at UCLA. Dr. Hedrick has been a Director of Cytori Therapeutics, Inc. since October 2002. He obtained his MD degree from the University of Texas Southwestern Medical School, Dallas and an M.B.A. from UCLA Anderson School of Management.

CEO Compensation
  • Marc's compensation has increased whilst company is loss making.
  • Marc's remuneration is higher than average for companies of similar size in Germany.
Management Team

Marc Hedrick

TITLE
CEO, President & Director
COMPENSATION
$846K
AGE
55
TENURE
5 yrs

Gary Titus

TITLE
Chief Financial Officer
AGE
58

John Fraser

TITLE
Chief Scientist
AGE
57

Russ Havranek

TITLE
Vice President of Global Marketing
TENURE
2.7 yrs
Board of Directors Tenure

Average tenure and age of the Cytori Therapeutics board of directors in years:

2.2
Average Tenure
57.5
Average Age
  • The average tenure for the Cytori Therapeutics board of directors is less than 3 years, this suggests a new board.
Board of Directors

Rick Hawkins

TITLE
Chairman of the Board
COMPENSATION
$72K
AGE
69
TENURE
1.3 yrs

Marc Hedrick

TITLE
CEO, President & Director
COMPENSATION
$846K
AGE
55
TENURE
16.5 yrs

Ron Martell

TITLE
Independent Director
COMPENSATION
$127K
AGE
56
TENURE
2.3 yrs

Gregg Lapointe

TITLE
Independent Director
COMPENSATION
$120K
AGE
59
TENURE
2.1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Cytori Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Cytori Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

XMPN News

Simply Wall St News

XMPN Company Info

Description

Cytori Therapeutics, Inc., a therapeutics company, together with its subsidiaries, develops regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for various medical conditions. Its lead drug candidate, ATI-0918, is a generic version of pegylated liposomal encapsulated doxorubicin, which is in Phase III clinical trial and used for various cancer types. The company’s second nanomedicine drug candidate is, ATI-1123, a novel and new chemical entity, which has completed Phase I clinical trial and is a workhorse chemotherapeutic drug used for various cancers. It also sells Celution cell processing systems, StemSource cell and tissue banking systems, and surgical accessories and instrumentation to hospitals, clinics, physicians, researchers, and other customers for commercial and research purposes through a combination of a direct sales force, third-party distributors, independent sales representatives, and licensees. In addition, the company markets and sells its proprietary enzymatic reagents under the Celase and Intravase brands. It has operations in the Americas, Japan, EMEA, and the Asia Pacific. Cytori Therapeutics, Inc. was founded in 1996 and is headquartered in San Diego, California.

Details
Name: Cytori Therapeutics, Inc.
XMPN
Exchange: DB
Founded: 1996
$6,263,305
21,905,795
Website: http://www.cytori.com
Address: Cytori Therapeutics, Inc.
3020 Callan Road,
San Diego,
California, 92121,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM CYTX Common Stock Nasdaq Capital Market US USD 10. Aug 2000
DB XMPN Common Stock Deutsche Boerse AG DE EUR 10. Aug 2000
Number of employees
Current staff
Staff numbers
37
Cytori Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/24 21:01
End of day share price update: 2019/04/24 00:00
Last estimates confirmation: 2019/04/02
Last earnings filing: 2019/03/29
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.